Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: MPA Hiding in Plain Sight

Benjamin Aronow, MD, Eduardo Mantovani Cardoso, MD, Steffi Thomas, DO, Prashant Grover, MD, & Weishali Joshi, MD  |  May 12, 2022

The COVID-19 pandemic has filled hospitals with patients with rapidly progressive respiratory failure and diffuse bilateral opacities on chest X-ray.1 Additionally, many patients with severe COVID-19 develop acute kidney injury and require dialysis.2 Pulmonary-renal syndromes are also important to consider in this setting. Although alveolar hemorrhage is a cardinal feature of this syndrome, many patients…

Set Up to Fail: The Criminalization of Clinical Practice

Philip Seo, MD, MHS  |  May 12, 2022

On Dec. 27, 2017, RaDonda Vaught killed Charlene Murphey, allegedly. Ms. Murphey was a lifelong resident of Gallatin, a suburb of Nashville, Tenn. She was well known from having worked at the local Walmart for 24 years, before she retired in 2012, when she was 65 years old.1 On Dec. 24, 2017, she was helping…

Bernard Chantal / shutterstock.com

Diagnostic Challenges of MIS-C

Brian L.P. Dizon, MD, PhD, & Sangeeta Sule, MD, PhD  |  May 12, 2022

During the peak of the coronavirus pandemic in Washington, D.C., we were asked to evaluate a 14-year-old boy admitted to the pediatric hospitalist service. He had been healthy until two weeks before, when he noted a sore throat, and soon after he developed fevers and rashes without congestion, shortness of breath, conjunctivitis or swollen lymph…

Case Report: Lipoma Arborescens of the Knee

John Nawrocki, MD, Kevin Hess, DO, & Maryah Mansoor, MBBS  |  May 12, 2022

Lipoma arborescens is a rare, benign intra-articular lesion characterized by diffuse replacement of synovial tissue by mature adipocytes, causing a villous lipomatous proliferation of the synovial membrane.1 Typically, this is a mono­articular condition, with the knee being the most commonly affected although it has been rarely reported to occur in an oligo-/polyarticular fashion and in…

Brandon Crawford / shutterstock.com

Case Report: Blunt Smoker Denies Tobacco Use, Delaying Diagnosis

Rachel E. Elam, MD, ScM, Vishal Arora, MD, & Alyce M. Oliver, PhD, MD  |  May 12, 2022

Cannabis arteritis mirrors thrombo­angiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight into how cannabis may…

Case Report: An Uncommon Incidental Finding

Mia Robb Stahler & Michael Rosen, M  |  May 11, 2022

In certain ethnic populations and geographic locations, being a genetic carrier of sickle cell trait is common. Despite its prevalence, a recent report studied 100 mothers who were informed their newborn child had tested positive for sickle cell trait, and of these mothers less than half were aware of their carrier status prior to conception.1…

Medication Preferences & Current Practices for PsA

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2022

With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.

Intra-Articular Steroid/Lidocaine Injection Improves Hip Arthritis Pain, Function

Reuters Staff  |  May 10, 2022

NEW YORK (Reuters Health)—A single injection into the hip of steroid and local anesthetic improved pain and function in patients with hip osteoarthritis in a randomized controlled trial, with most of the benefit seen early after treatment. Researchers at two community-based clinics in England assigned 199 volunteers to receive either an ultrasound guided intra-articular hip…

Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

Michele B. Kaufman, PharmD, BCGP  |  May 9, 2022

In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

Imaging of Axial Psoriatic Arthritis

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  May 9, 2022

The axial phenotype of psoriatic arthritis (axPsA) is an excellent example of a major controversy in rheumatology that has become the focus of attention because of the emergence of new therapies with different mechanisms of action for alleviating joint inflammation. It was first described in 1961 but, until recently, it has largely remained under the…

  • « Previous Page
  • 1
  • …
  • 103
  • 104
  • 105
  • 106
  • 107
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences